Novacyt S.A [ALNOV] vs Median Technologies [ALMDT] Detailed Stock Comparison
Novacyt S.A
Euronext
Loading...
Median Technologies
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Novacyt S.A wins in 7 metrics, Median Technologies wins in 8 metrics, with 0 ties. Median Technologies appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novacyt S.A | Median Technologies | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.80 | -1.84 | Median Technologies |
| Price-to-Book Ratio | 0.70 | N/A | N/A |
| Debt-to-Equity Ratio | 24.81 | -0.98 | Median Technologies |
| PEG Ratio | 1.83 | N/A | N/A |
| EV/EBITDA | -1.30 | -3.39 | Median Technologies |
| Profit Margin (TTM) | -212.73% | -109.93% | Median Technologies |
| Operating Margin (TTM) | -84.87% | -76.84% | Median Technologies |
| Return on Equity | -57.28% | 74.31% | Median Technologies |
| Return on Assets (TTM) | -10.19% | -46.71% | Novacyt S.A |
| Free Cash Flow (TTM) | $-12.71M | $-19.03M | Novacyt S.A |
| 1-Year Return | -58.97% | -66.28% | Novacyt S.A |
| Price-to-Sales Ratio (TTM) | 1.77 | 3.99 | Novacyt S.A |
| Enterprise Value | $16.98M | $75.26M | Median Technologies |
| EV/Revenue Ratio | 0.75 | 3.28 | Novacyt S.A |
| Revenue per Share (TTM) | $0 | $1 | Median Technologies |
| Earnings per Share (Diluted) | $-0.64 | $-1.37 | Novacyt S.A |
| Beta (Stock Volatility) | 0.10 | 0.65 | Novacyt S.A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Novacyt S.A vs Median Technologies Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novacyt S.A | -1.46% | -2.04% | 2.13% | 2.13% | -18.64% | -21.31% |
| Median Technologies | 9.79% | -12.31% | 14.08% | 5.38% | -10.31% | -44.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novacyt S.A | -58.97% | -57.14% | -85.88% | -89.33% | -94.34% | -94.34% |
| Median Technologies | -66.28% | -77.83% | -63.62% | -81.92% | -68.41% | -68.41% |
Performance & Financial Health Analysis: Novacyt S.A vs Median Technologies
| Metric | ALNOV | ALMDT |
|---|---|---|
| Market Information | ||
| Market Cap | €34.83M | €91.70M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 307,576 | 427,815 |
| 90 Day Avg. Volume | 169,105 | 344,221 |
| Last Close | €0.47 | €2.58 |
| 52 Week Range | €0.42 - €1.38 | €1.19 - €7.47 |
| % from 52W High | -65.72% | -65.46% |
| All-Time High | €13.96 (Oct 26, 2020) | €18.32 (Oct 18, 2021) |
| % from All-Time High | -96.63% | -85.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.06% |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -2.13% | -1.10% |
| Operating Margin (TTM) | -0.85% | -0.77% |
| Return on Equity (TTM) | -0.57% | 0.74% |
| Debt to Equity (MRQ) | 24.81 | -0.98 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.68 | €-1.84 |
| Cash per Share (MRQ) | €0.43 | €0.45 |
| Operating Cash Flow (TTM) | €-11,388,786 | €-17,949,000 |
| Levered Free Cash Flow (TTM) | €7.16M | €-12,399,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Novacyt S.A vs Median Technologies
| Metric | ALNOV | ALMDT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.80 | -1.84 |
| Forward P/E | 1.83 | -2.41 |
| PEG Ratio | 1.83 | N/A |
| Price to Sales (TTM) | 1.77 | 3.99 |
| Price to Book (MRQ) | 0.70 | N/A |
| Market Capitalization | ||
| Market Capitalization | €34.83M | €91.70M |
| Enterprise Value | €16.98M | €75.26M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.75 | 3.28 |
| Enterprise to EBITDA | -1.30 | -3.39 |
| Risk & Other Metrics | ||
| Beta | 0.10 | 0.65 |
| Book Value per Share (MRQ) | €0.68 | €-1.84 |
Financial Statements Comparison: Novacyt S.A vs Median Technologies
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALNOV | ALMDT |
|---|---|---|
| Revenue/Sales | N/A | N/A |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | N/A |
| EBITDA | N/A | N/A |
| Pre-Tax Income | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALNOV | ALMDT |
|---|---|---|
| Cash & Equivalents | €35.16M | €8.13M |
| Total Current Assets | €45.46M | €20.52M |
| Total Current Liabilities | €7.18M | €44.10M |
| Long-Term Debt | €12.26M | €8.99M |
| Total Shareholders Equity | €55.28M | €-33.97M |
| Retained Earnings | €-13.50M | €-25.24M |
| Property, Plant & Equipment | €0 | €5.90M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALNOV | ALMDT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALNOV | ALMDT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 307,576 | 427,815 |
| Average Daily Volume (90 Day) | 169,105 | 344,221 |
| Shares Outstanding | 81.88M | 18.42M |
| Float Shares | 70.58M | 16.50M |
| % Held by Insiders | 0.00% | 0.14% |
| % Held by Institutions | 0.00% | 0.10% |
Dividend Analysis & Yield Comparison: Novacyt S.A vs Median Technologies
| Metric | ALNOV | ALMDT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |